Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Dosing of Pembrolizumab and Axitinib in Advanced Clear Cell Renal Cell Carcinoma
NCT06860386Phase 2Suspended
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2025
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and axitinib in clear cell renal cell carcinoma (ccRCC), sponsored by Moffitt Cancer Center. Primary endpoints: Recruitment Rate Feasibility at 36 months and Progression-Free Survival at 12 months. Started Feb 2025; status: suspended.
02
Drugs
pembrolizumabaxitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06860386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860386.